SC
GTBP icon

Swan Capital’s GT Biopharma GTBP Stock Holding History

Swan Capital’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$785 – 583
2025
Q4 		$785 Buy
+1,000
New +$710 ﹤0.01% 424

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Swan Capital's GTBP Position: Q1 2026 in Review

Swan Capital sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 1,000 shares — an estimated $785 sold.

Swan Capital first reported a position in GTBP in Q4 2025 and held it in 1 quarter. The position peaked at $785 in Q4 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Swan Capital reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Swan Capital sold 1,000 GT Biopharma shares in Q1 2026, an estimated $785.
  • Swan Capital first reported a position in GT Biopharma in Q4 2025 and held it in 1 quarter.
  • Swan Capital's GT Biopharma position peaked at $785 in Q4 2025.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.